Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
10.4142/jvs.2016.17.3.431
- Author:
Jin Ok AHN
1
;
Qiang LI
;
Young Heun LEE
;
Sei Myoung HAN
;
Cheol Yong HWANG
;
Hwa Young YOUN
;
Jin Young CHUNG
Author Information
1. Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea. hyyoun@snu.ac.kr
- Publication Type:Case Report
- Keywords:
L-ornithin-L-aspartate;
dogs;
hepatic encephalopathy;
hyperammonemia
- MeSH:
Ammonia;
Animals;
Dogs*;
Dipeptides*;
Hepatic Encephalopathy*;
Hyperammonemia;
Lactulose;
Veterinary Medicine
- From:Journal of Veterinary Science
2016;17(3):431-433
- CountryRepublic of Korea
- Language:English
-
Abstract:
Seventeen dogs were treated with L-ornithin-L-aspartate (LOLA; experimental group). Three dogs were treated with lactulose recognized therapy (control group). Following LOLA administration, 15 dogs experienced a significant decrease in ammonia level (p < 0.05) and showed clinical signs of improvement. However, there were no clinical signs of improvement in two dogs, even though the ammonia level decreased. Conversely, the clinical signs of the control group also improved and the ammonia level decreased, although these changes were not significant (p > 0.05). These results suggest that LOLA is an effective drug to treat hyperammonemia in veterinary medicine.
